The Cigna Group provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care delivery and management, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans to on and off the public exchanges; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

The Cigna Group

Cigna Group's stock has dropped since Thursday, coinciding with a social media post published after market hours that discusses a forthcoming Repub...

Cigna Group's stock declines amid concerns over a Republican healthcare plan targeting pharmacy benefit managers. The plan's potential impact on dr...

Cigna Group's stock has experienced a notable decline over the past year, dropping significantly while recently showing a monthly increase. The com...

Cigna Group's stock declines amid concerns over growth prospects. Its P/E ratio of 12.11 contrasts sharply with the industry average of 140.78.

Guggenheim analyst Jason Cassorla has raised the price target on Cigna Group (NYSE: CI) to 318.00 from 309.00, while maintaining a Buy rating. This...

Guggenheim's Jason Cassorla raises Cigna's price target to $318, maintaining a Buy rating. This reflects optimism about the company's growth potent...

Cigna Group's stock has increased following its recent inclusion on the US 1 List by Bank of America Merrill Lynch, a designation that typically si...

Cigna Group's stock rises after Bank of America Merrill Lynch includes it on the US 1 List, signaling strong performance potential. No other news i...

Cigna Group has introduced Clearity by Cigna Healthcare, a new copay-only health plan designed to simplify healthcare costs for consumers. This ini...

Cigna launches Clearity, a copay-only health plan. Market reacts positively to Medicare premium updates and U.S. Factory Orders data.

Cigna Group has announced its participation in the 2025 UBS Global Healthcare Conference, set for November 12, 2025, in Palm Beach Gardens, FL. Ann...

Cigna Group engages in strategic partnerships to tackle GLP-1 drug pricing. Upcoming conference presentation highlights robust financial health and...

Cigna Healthcare has announced a collaboration with Headspace to enhance mental health support for its customers. This initiative aims to provide s...

Cigna partners with Headspace to combat rising worker anxiety. This initiative offers free mental health resources, addressing stress and sleep iss...

Cigna Group's stock has increased by 3.2% during market hours on Friday. A Bloomberg report has highlighted that a unit of the company is selling g...

Cigna Group's stock rises amid concerns over high generic drug prices. Social media buzz and a recent report suggest this may drive investor interest.

Cigna Group's stock has declined in tandem with the broader market, which is experiencing significant downward movement. In company-specific news,...

Cigna's stock declines amid broader market drop. Dr. Amy Flaster's new role aims to enhance clinical excellence and innovative care models.

Cigna Group's stock has dropped significantly, moving down by 1.5% since Tuesday. In a recent report, Wells Fargo analyst Stephen Baxter lowered th...

Cigna Group's stock declines after Wells Fargo cuts price target to $300. Analyst maintains Equal Weight rating amid market uncertainty.

Cigna Group has recently faced several updates from analysts regarding its price targets. JP Morgan maintained an Overweight rating while reducing...

Analysts cut Cigna's price targets amid margin pressure. Concerns stem from declining earnings in pharmacy benefit services through 2027.

Cigna Group's CEO David Cordani acquired 4,134 shares at a weighted average price of 241.88 on November 3, 2025. Following this transaction, he hol...

Cigna's CEO David Cordani acquired 4,134 shares, boosting his total to 621,189. This move signals confidence amid rising stock momentum.

Truist Securities analyst David MacDonald has lowered the price target for Cigna Group (NYSE: CI) to 310.00 from 375.00, while maintaining a Buy ra...

Analysts lower Cigna's price targets amid declining shares. Truist sees 310, Morgan Stanley at 355, signaling market concerns.

Cigna Group logged higher profit and revenue in the third quarter, boosted by continued strength in its pharmacy-benefit business Evernorth.